Enveric Biosciences adds $2.4M to ATM program
Enveric Biosciences, Inc. filed an 8-K to report that on June 9, 2026 it filed a prospectus supplement to offer an additional $2,425,000 of shares of its common stock under its existing at-the-market equity offering program with H.C.
Rhea-AI Filing Summary
Enveric Biosciences, Inc. filed an 8-K to report that on June 9, 2026 it filed a prospectus supplement to offer an additional $2,425,000 of shares of its common stock under its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC as sales agent. Prior to this date, the company had sold an aggregate of $4,483,711.04 through the sales agent under the same agreement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the shares is included as an exhibit.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional ATM capacity: $2,425,000 of common stock
Prior ATM sales: $4,483,711.04 of common stock
Form type: Current report on Form 8-K
3 metrics
Additional ATM capacity
$2,425,000 of common stock
Prospectus supplement dated June 9, 2026
Prior ATM sales
$4,483,711.04 of common stock
Aggregate sold before June 9, 2026
Form type
Current report on Form 8-K
Item 8.01 Other Events
Key Terms
prospectus supplement, At The Market Offering Agreement, emerging growth company, legal opinion, +1 more
5 terms
prospectus supplement regulatory
"filed a prospectus supplement (the “Prospectus Supplement”) to offer an additional $2,425,000"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
At The Market Offering Agreement financial
"pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
legal opinion regulatory
"An opinion regarding the legality of the Shares issuable under the ATM Agreement"
Sales Agent financial
"through the Sales Agent under the ATM Agreement"
A sales agent is an individual or firm authorized to sell a company’s products or services on its behalf, typically paid by commission or fees rather than a fixed salary. For investors, who a company uses to reach customers and how well those agents perform affects revenue growth and profit margins — like hiring local independent sellers to expand into new neighborhoods without building stores — so agent quality and cost matter to future cash flow and valuation.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Enveric Biosciences (ENVB) disclose in its latest 8-K?
Enveric Biosciences disclosed that it filed a prospectus supplement to offer additional common stock under an existing at-the-market equity program. The filing also includes a legal opinion from Greenberg Traurig, LLP regarding the validity of the shares covered by this prospectus supplement.
How large is Enveric Biosciences’ new at-the-market stock offering capacity?
The company’s prospectus supplement allows it to offer an additional $2,425,000 of common stock under its existing at-the-market program. This amount represents incremental capacity on top of what has already been sold through the arrangement with H.C. Wainwright & Co., LLC.
How much has Enveric Biosciences already sold under its ATM agreement?
Enveric Biosciences has previously sold an aggregate of $4,483,711.04 of common stock through H.C. Wainwright & Co., LLC under the at-the-market offering agreement. These earlier sales occurred before the June 9, 2026 prospectus supplement for additional shares.
Who is the sales agent for Enveric Biosciences’ at-the-market stock offering?
H.C. Wainwright & Co., LLC serves as the sales agent for Enveric Biosciences’ at-the-market offering of common stock. The arrangement is governed by an At The Market Offering Agreement originally dated April 9, 2025 and referenced in the June 9, 2026 filing.
What legal documents accompany Enveric Biosciences’ new stock offering?
The filing includes a legal opinion from Greenberg Traurig, LLP addressing the legality of the shares issued under the at-the-market agreement. A related consent from the same firm is also included, along with an interactive data file for the cover page information.
Is Enveric Biosciences identified as an emerging growth company in this filing?
Enveric Biosciences is identified as an emerging growth company under applicable Securities Exchange Act rules. This designation can allow certain reduced disclosure and compliance requirements compared with larger, more established public companies, depending on the specific regulatory provisions involved.
AI-generated analysis. How Rhea-AI works. Not financial advice.
